XBIO (Xenetic Biosciences) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 27, 2026)


XBIO Xenetic Biosciences Inc XBIO
83 GF Score
Price $2.95
GF Value $4.18
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Xenetic Biosciences Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Xenetic Biosciences's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

XBIO vs PCSA, SILO, LIMN: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Xenetic Biosciences's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xenetic Biosciences Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xenetic Biosciences's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Xenetic Biosciences's Margin of Safety % (DCF Earnings Based) falls into.


XBIO
83GF Score
Xenetic Biosciences Inc XBIO
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Xenetic Biosciences (XBIO) Overvalued in 2026?

Based on GuruFocus' analysis, Xenetic Biosciences stock appears to be undervalued. The current stock price of $2.95 is trading 29.5% below its estimated GF Value™ of $4.18. GuruFocus considers Xenetic Biosciences to be Possible Value Trap.

Key valuation signals for XBIO:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: $4.18 vs. price of $2.95 (29.5% below fair value)
  • GF Score™: 83/100 with 2 warning signs

No single metric tells the full story. See the XBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xenetic Biosciences Business Description

Address 945 Concord Street, Framingham, MA, USA, 01701
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
83GF Score

Get the complete analysis for XBIO

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.95
Price
$4.18
GF Value